

Edgar Filing: APPLERA CORP - Form 8-K

APPLERA CORP
Form 8-K
October 24, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

October 24, 2001
Date of Report (Date of earliest event reported)

APPLERA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

1-4389
(Commission
File No.)

06-1534213
(IRS Employer
Identification No.)

301 Merritt 7
Norwalk, Connecticut 06851
(Address of Principal Executive Offices, Including Zip Code)

(203) 840-2000
(Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 and 99.2 and incorporated by reference herein are the texts of press releases (the "Press Releases") issued October 24, 2001 by Applera Corporation ("Applera") regarding fiscal year 2002 first quarter results for Applera's Applied Biosystems and Celera Genomics groups.

Beginning in the fourth quarter of fiscal year 2001, Applera's Applied Biosystems group commenced the reporting of net revenues by product category. For reference purposes, the comparable classification of quarterly net revenues for fiscal year 2001 is as follows:

Edgar Filing: APPLERA CORP - Form 8-K

Revenues (Dollar amounts in millions)	Q1	Q2	Q3	Q4	
-----	--	--	--	--	
Instruments, including software	\$185.0	\$207.7	\$229.2	\$191.4	\$
Percent of Net Revenues	50.9%	50.5%	52.1%	47.2%	
Consumables	\$124.5	\$150.3	\$159.0	\$158.3	\$
Percent of Net Revenues	34.2%	36.6%	36.2%	39.1%	
Other Sources	\$ 54.1	\$ 53.0	\$ 51.6	\$ 55.4	\$
Percent of Net Revenues	14.9%	12.9%	11.7%	13.7%	
Net Revenues	\$363.6	\$411.0	\$439.8	\$405.1	\$

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

The following exhibits are filed with this Report:

Exhibit No.	Description
99.1	Press Release issued October 24, 2001 with respect to the Applied Biosystems group.
99.2	Press Release issued October 24, 2001 with respect to the Celera Genomics group.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APPLERA CORPORATION

By: /s/ Dennis L. Winger

Dennis L. Winger
Senior Vice President and
Chief Financial Officer

Dated: October 24, 2001

Edgar Filing: APPLERA CORP - Form 8-K

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued October 24, 2001 with respect to the Applied Biosystems group.
99.2	Press Release issued October 24, 2001 with respect to the Celera Genomics group.